Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 382

1.

Ischemia-Reperfusion Injury in Marginal Liver Grafts and the Role of Hypothermic Machine Perfusion: Molecular Mechanisms and Clinical Implications.

Czigany Z, Lurje I, Schmelzle M, Schöning W, Öllinger R, Raschzok N, Sauer IM, Tacke F, Strnad P, Trautwein C, Neumann UP, Fronek J, Mehrabi A, Pratschke J, Schlegel A, Lurje G.

J Clin Med. 2020 Mar 20;9(3). pii: E846. doi: 10.3390/jcm9030846. Review.

2.

Primary Neuroendocrine Neoplasms of the Breast: Case Series and Literature Review.

Özdirik B, Kayser A, Ullrich A, Savic LJ, Reiss M, Tacke F, Wiedenmann B, Jann H, Roderburg C.

Cancers (Basel). 2020 Mar 20;12(3). pii: E733. doi: 10.3390/cancers12030733. Review.

3.

From the Editor's Desk...

Burra P, Tacke F, Ratziu V, Zeuzem S, Sangro B, Angeli P.

J Hepatol. 2020 Apr;72(4):597-600. doi: 10.1016/j.jhep.2020.01.001. No abstract available.

PMID:
32192708
4.

Recent Advances in Practical Methods for Liver Cell Biology: A Short Overview.

Torres S, Abdullah Z, Brol MJ, Hellerbrand C, Fernandez M, Fiorotto R, Klein S, Königshofer P, Liedtke C, Lotersztajn S, Nevzorova YA, Schierwagen R, Reiberger T, Uschner FE, Tacke F, Weiskirchen R, Trebicka J.

Int J Mol Sci. 2020 Mar 16;21(6). pii: E2027. doi: 10.3390/ijms21062027. Review.

5.

Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism.

Lefere S, Tacke F.

JHEP Rep. 2019 Feb 23;1(1):30-43. doi: 10.1016/j.jhepr.2019.02.004. eCollection 2019 May. Review.

6.

Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer.

Loosen SH, Breuer A, Tacke F, Kather JN, Gorgulho J, Alizai PH, Bednarsch J, Roeth AA, Lurje G, Schmitz SM, Brozat JF, Paffenholz P, Vucur M, Ritz T, Koch A, Trautwein C, Ulmer TF, Roderburg C, Longerich T, Neumann UP, Luedde T.

JHEP Rep. 2020 Jan 31;2(2):100080. doi: 10.1016/j.jhepr.2020.100080. eCollection 2020 Apr.

7.

From the Editor's Desk….

Burra P, Tacke F, Ratziu V, Zeuzem S, Sangro B, Angeli P.

J Hepatol. 2020 Mar;72(3):379-383. doi: 10.1016/j.jhep.2019.12.012. No abstract available.

PMID:
32067655
8.

Non-invasive assessment for alpha-1 antitrypsin deficiency-associated liver disease: new insights on steatosis and fibrosis in Pi*ZZ carriers.

Roohani S, Tacke F.

Transl Gastroenterol Hepatol. 2019 Dec 12;4:82. doi: 10.21037/tgh.2019.11.13. eCollection 2019. No abstract available.

9.

Current status of immunotherapy in gastrointestinal malignancies.

Lorenzen S, Lordick F, Loosen SH, Tacke F, Trautwein C, Roderburg C, Ettrich TJ, Perkhofer L, Reinacher-Schick A, Stein A.

Z Gastroenterol. 2020 Feb 4. doi: 10.1055/a-1071-8322. [Epub ahead of print]

PMID:
32018315
10.

Liver impairment in critical illness and sepsis: the dawn of new biomarkers?

Kluge M, Tacke F.

Ann Transl Med. 2019 Dec;7(Suppl 8):S258. doi: 10.21037/atm.2019.12.79. No abstract available.

11.

Risk Prediction for Acute Kidney Injury - Super Important, Now suPAR Easy?

Tacke F.

N Engl J Med. 2020 Jan 30;382(5):470-472. doi: 10.1056/NEJMe1916796. No abstract available.

PMID:
31995696
12.

Elevated circulating CD14++CD16+ intermediate monocytes are independently associated with extracardiac complications after cardiac surgery.

Mossanen JC, Jansen TU, Pracht J, Liepelt A, Buendgens L, Stoppe C, Goetzenich A, Simon TP, Autschbach R, Marx G, Tacke F.

Sci Rep. 2020 Jan 22;10(1):947. doi: 10.1038/s41598-020-57700-9.

13.

Regeneration in acute-on-chronic liver failure - the phantom lost its camouflage.

Engelmann C, Mehta G, Tacke F.

J Hepatol. 2020 Apr;72(4):610-612. doi: 10.1016/j.jhep.2020.01.003. Epub 2020 Jan 15. No abstract available.

PMID:
31953140
14.

Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges.

Lefere S, Devisscher L, Tacke F.

Expert Opin Investig Drugs. 2020 Feb;29(2):89-92. doi: 10.1080/13543784.2020.1718106. Epub 2020 Jan 20. No abstract available.

PMID:
31952447
15.

Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E.

Schulz M, Biedermann P, Bock CT, Hofmann J, Choi M, Tacke F, Hanitsch LG, Mueller T.

Int J Environ Res Public Health. 2020 Jan 3;17(1). pii: E341. doi: 10.3390/ijerph17010341.

16.

Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.

Ratziu V, Sanyal A, Harrison SA, Wong VW, Francque S, Goodman Z, Aithal GP, Kowdley KV, Seyedkazemi S, Fischer L, Loomba R, Abdelmalek MF, Tacke F.

Hepatology. 2020 Jan 13. doi: 10.1002/hep.31108. [Epub ahead of print]

PMID:
31943293
17.

Differential Gene Expression in Circulating CD14+ Monocytes Indicates the Prognosis of Critically Ill Patients with Sepsis.

Liepelt A, Hohlstein P, Gussen H, Xue J, Aschenbrenner AC, Ulas T, Buendgens L, Warzecha KT, Bartneck M, Luedde T, Trautwein C, Schultze JL, Koch A, Tacke F.

J Clin Med. 2020 Jan 2;9(1). pii: E127. doi: 10.3390/jcm9010127.

18.

Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design.

Anstee QM, Neuschwander-Tetri BA, Wong VW, Abdelmalek MF, Younossi ZM, Yuan J, Pecoraro ML, Seyedkazemi S, Fischer L, Bedossa P, Goodman Z, Alkhouri N, Tacke F, Sanyal A.

Contemp Clin Trials. 2019 Dec 24;89:105922. doi: 10.1016/j.cct.2019.105922. [Epub ahead of print]

19.

From the Editor's Desk….

Burra P, Tacke F, Ratziu V, Zeuzem S, Sangro B, Angeli P.

J Hepatol. 2020 Jan;72(1):1-4. doi: 10.1016/j.jhep.2019.11.002. No abstract available.

PMID:
31849346
20.

Elevated MR-proANP plasma concentrations are associated with sepsis and predict mortality in critically ill patients.

Yagmur E, Sckaer JH, Koek GH, Weiskirchen R, Trautwein C, Koch A, Tacke F.

J Transl Med. 2019 Dec 12;17(1):415. doi: 10.1186/s12967-019-02165-2.

Supplemental Content

Loading ...
Support Center